Market cap
$371 Mln
Revenue (TTM)
$82 Mln
P/E Ratio
45.9
P/B Ratio
2.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
51.35
-
EV/EBITDA
18.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
20,224,838
10 Years Aggregate
CFO
$122.67 Mln
EBITDA
$107.29 Mln
Net Profit
$80.53 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Simulations Plus (SLP)
| 0.5 | 0.7 | 25.5 | 38.5 | -28.3 | -16.6 | 8.8 |
|
BSE Sensex*
| -8.4 | 0.6 | 0.9 | -4.1 | 5.5 | 8.1 | 10.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Simulations Plus (SLP)
| -34.6 | -37.4 | 22.4 | -22.7 | -34.2 | 147.4 | 46.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Simulations Plus (SLP)
|
18.3 | 370.9 | 82.1 | 8.1 | 13.2 | 6.1 | 45.9 | 2.7 |
| 14.3 | 561.7 | 320.2 | -36.7 | -11.2 | -20.8 | -- | 3.3 |
Shareholding Pattern
View DetailsAbout Simulations Plus (SLP)
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through... Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina. Read more
-
Co-Founder & Chairman
Dr. Walter S. Woltosz M.A.S., M.S.
-
Co-Founder & Chairman
Dr. Walter S. Woltosz M.A.S., M.S.
-
Headquarters
Research Triangle Park, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Simulations Plus (SLP)
What is the current share price of Simulations Plus Inc (SLP) Today?
The share price of Simulations Plus Inc (SLP) is $18.33 (NASDAQ) as of 28-Jul-2026 16:00 EDT. Simulations Plus Inc (SLP) has given a return of -28.33% in the last 3 years.
What is the current PB & PE ratio of Simulations Plus Inc (SLP)?
The P/E ratio of Simulations Plus Inc (SLP) is 45.85 times as on 24-Jul-2026, a 11 discount to its peers’ median range of 51.35 times.
The P/B ratio of Simulations Plus Inc (SLP) is 2.67 times as on 24-Jul-2026, a 22 discount to its peers’ median range of 3.42 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Simulations Plus Inc (SLP)?
The 52-week high and low of Simulations Plus Inc (SLP) are Rs 21.01 and Rs 11.09 as of 29-Jul-2026.
What is the market cap of Simulations Plus Inc (SLP)?
Simulations Plus Inc (SLP) has a market capitalisation of $ 371 Mln as on 24-Jul-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Simulations Plus Inc (SLP)?
Before investing in Simulations Plus Inc (SLP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.